Search - tctmd.com

Displaying 1 - 20 of 135

Sort: Relevancy | Date

Presentation ESC 2025

Mavacamten in Symptomatic Nonobstructive Cardiomyopathy: Primary results of the ODYSSEY-HCM Trial

Presenter: Milind Y Desai

August 30, 2025

Presentation THT 2025

Kansas City Cardiomyopathy Questionnaire: Why All the Fuss?

Presenter: JoAnn Lindenfeld

February 13, 2025

Presentation THT 2025

Evidence That Challenges the Validity of KCCQ as a Measure of Quality of Life in Both Blinded and Unblinded Studies

Presenter: Gregg Stone

February 13, 2025

Presentation THT 2025

Evidence Supporting the Use of KCCQ as a Valid Measure of Quality of Life in Both Blinded and Unblinded Studies

Presenter: David Cohen

February 13, 2025

Presentation THT 2025

Gene Therapy to Reverse Acquired Cardiomyopathy and Recover Chronic Heart Failure

Presenter: Robin Shaw

February 12, 2025

Presentation THT 2025

Myeloperoxidase Inhibition in Patients With Ischemic or Non-Ischemic Cardiomyopathy and Heart Failure With Reduced Ejection Fraction (MYSTERY-HF)

Presenter: Simon Braumann

February 12, 2025

Presentation THT Abstracts 2025

Outcomes of Sodium-Glucose Cotransporter 2 Inhibitor Use in Cardiac Sarcoidosis Cardiomyopathy

Presenter: Ahmed Mahmoud

February 11, 2025

Presentation THT 2025

Outcomes of Sodium-Glucose Cotransporter 2 Inhibitor Use in Cardiac Sarcoidosis Cardiomyopathy

Presenter: Ahmed Mahmoud

February 11, 2025

Presentation THT 2025

Gene Therapy for HCM: Is a Cure Coming?

Presenter: Nosheen Reza

February 11, 2025

Presentation THT 2025

Are We Ever Going to Have New Medical Therapy Options for Nonobstructive HCM?

Presenter: Anjali Owens

February 11, 2025

Presentation THT 2025

Current Evidence for Cardiac Myosin Inhibitors: Where Are We in 2025?

Presenter: Martin Maron

February 11, 2025

Presentation THT 2025

Surgical Myectomy: Still the Gold Standard for Obstructive HCM?

Presenter: Hiroo Takayama

February 11, 2025

Presentation THT 2025

Will Novel Catheter Based Approaches Save the Day?

Presenter: Jaffar Khan

February 11, 2025

Presentation THT 2025

Case-in-the-Box: SESAME

Presenter: Adam Greenbaum

February 11, 2025

Presentation THT 2025

The Catecholaminergic Theory of Takotsubo in Action: A Case of Fulminant Stress Cardiomyopathy Rescued by ECPR in a Young Woman With Pheochromocytoma

Presenter: Alexander Smith

February 11, 2025

Presentation TCT 2024

Controlled Pulmonary Banding for Dilated Cardiomyopathy: the Restore Medical Approach

Presenter: Sean Pinney

October 28, 2024

Presentation TCT 2024

TCT 475: Long-Term Outcomes of Simultaneous Interventional Treatment for Hypertrophic Obstructive Cardiomyopathy and Concomitant Coronary Artery Disease

Presenter: Stanislav Fanta

October 27, 2024

Presentation TCT 2024

TCT 478: Socioeconomic Disparities in Patients Undergoing Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: A 5-Year National Experience

Presenter: Himaja Dutt Chigurupati

October 27, 2024

Presentation TCT 2024

TCT 479: Incomplete Resolution of Left Ventricular Outflow Tract Gradient After Alcohol Septal Ablation Is Predictive of Need for Reintervention in Hypertrophic Obstructive Cardiomyopathy: A Retrospective Cohort Study

Presenter: Kylie Duckworth

October 27, 2024

Presentation TCT 2024

TCT 477: Procedural Outcomes in 25 Years of Alcohol Septal Ablations at a Tertiary Level Medical Center

Presenter: Nikhil Rao

October 27, 2024

Advertisement

Mavacamten in Symptomatic Nonobstructive Cardiomyopathy: Primary results of the ODYSSEY-HCM Trial

Kansas City Cardiomyopathy Questionnaire: Why All the Fuss?

Evidence That Challenges the Validity of KCCQ as a Measure of Quality of Life in Both Blinded and Unblinded Studies

Evidence Supporting the Use of KCCQ as a Valid Measure of Quality of Life in Both Blinded and Unblinded Studies

Gene Therapy to Reverse Acquired Cardiomyopathy and Recover Chronic Heart Failure

Myeloperoxidase Inhibition in Patients With Ischemic or Non-Ischemic Cardiomyopathy and Heart Failure With Reduced Ejection Fraction (MYSTERY-HF)

Outcomes of Sodium-Glucose Cotransporter 2 Inhibitor Use in Cardiac Sarcoidosis Cardiomyopathy

Outcomes of Sodium-Glucose Cotransporter 2 Inhibitor Use in Cardiac Sarcoidosis Cardiomyopathy

Gene Therapy for HCM: Is a Cure Coming?

Are We Ever Going to Have New Medical Therapy Options for Nonobstructive HCM?

Current Evidence for Cardiac Myosin Inhibitors: Where Are We in 2025?

Surgical Myectomy: Still the Gold Standard for Obstructive HCM?

Will Novel Catheter Based Approaches Save the Day?

Case-in-the-Box: SESAME

The Catecholaminergic Theory of Takotsubo in Action: A Case of Fulminant Stress Cardiomyopathy Rescued by ECPR in a Young Woman With Pheochromocytoma

Controlled Pulmonary Banding for Dilated Cardiomyopathy: the Restore Medical Approach

TCT 475: Long-Term Outcomes of Simultaneous Interventional Treatment for Hypertrophic Obstructive Cardiomyopathy and Concomitant Coronary Artery Disease

TCT 478: Socioeconomic Disparities in Patients Undergoing Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: A 5-Year National Experience

TCT 479: Incomplete Resolution of Left Ventricular Outflow Tract Gradient After Alcohol Septal Ablation Is Predictive of Need for Reintervention in Hypertrophic Obstructive Cardiomyopathy: A Retrospective Cohort Study

TCT 477: Procedural Outcomes in 25 Years of Alcohol Septal Ablations at a Tertiary Level Medical Center

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content